Ascendis Pharma A/S (ASND) Expected to Announce Earnings on Thursday

Ascendis Pharma A/S (NASDAQ:ASND) is expected to be posting its Q1 2026 results after the market closes on Thursday, April 30th. Analysts expect Ascendis Pharma A/S to post earnings of $0.33 per share and revenue of $376.1140 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Thursday, February 12th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.58). The firm had revenue of $290.38 million during the quarter, compared to analyst estimates of $285.35 million. On average, analysts expect Ascendis Pharma A/S to post $4 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Ascendis Pharma A/S Price Performance

Shares of ASND traded down $2.57 during mid-day trading on Wednesday, reaching $219.52. The company had a trading volume of 20,187 shares, compared to its average volume of 690,722. Ascendis Pharma A/S has a twelve month low of $150.89 and a twelve month high of $250.74. The company’s 50-day moving average is $231.44 and its 200-day moving average is $218.18. The company has a market capitalization of $13.69 billion, a P/E ratio of -49.98 and a beta of 0.49.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of hedge funds and other institutional investors have recently bought and sold shares of ASND. Perceptive Advisors LLC acquired a new stake in Ascendis Pharma A/S during the 2nd quarter valued at $166,367,000. Wellington Management Group LLP increased its holdings in Ascendis Pharma A/S by 95.9% during the 3rd quarter. Wellington Management Group LLP now owns 1,798,931 shares of the biotechnology company’s stock valued at $357,645,000 after purchasing an additional 880,836 shares in the last quarter. Vestal Point Capital LP increased its holdings in Ascendis Pharma A/S by 200.0% during the 3rd quarter. Vestal Point Capital LP now owns 600,000 shares of the biotechnology company’s stock valued at $119,286,000 after purchasing an additional 400,000 shares in the last quarter. Two Sigma Investments LP increased its holdings in Ascendis Pharma A/S by 5,803.2% during the 3rd quarter. Two Sigma Investments LP now owns 183,886 shares of the biotechnology company’s stock valued at $36,558,000 after purchasing an additional 180,771 shares in the last quarter. Finally, Jain Global LLC increased its holdings in Ascendis Pharma A/S by 502.1% during the 4th quarter. Jain Global LLC now owns 216,526 shares of the biotechnology company’s stock valued at $46,172,000 after purchasing an additional 180,564 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Bank of America increased their target price on Ascendis Pharma A/S from $262.00 to $292.00 and gave the stock a “buy” rating in a report on Thursday, April 16th. The Goldman Sachs Group reissued a “buy” rating and issued a $255.00 target price on shares of Ascendis Pharma A/S in a report on Monday, March 2nd. Wedbush reissued an “outperform” rating and issued a $273.00 target price on shares of Ascendis Pharma A/S in a report on Thursday, April 9th. Stifel Nicolaus set a $332.00 target price on Ascendis Pharma A/S in a report on Wednesday, March 4th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $256.00 target price on shares of Ascendis Pharma A/S in a report on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $291.56.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark?based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long?acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once?weekly growth hormone therapy approved by the U.S.